• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

Research Brief on tert-butyl (5S)-1,7-diazaspiro[4.4]nonane-1-carboxylate (CAS: 2323066-69-7) in Chemical Biology and Pharmaceutical Applications

The compound tert-butyl (5S)-1,7-diazaspiro[4.4]nonane-1-carboxylate (CAS: 2323066-69-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This spirocyclic scaffold is increasingly recognized for its role as a versatile intermediate in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and GPCR-targeting drugs. Recent studies highlight its utility in addressing challenges related to drug selectivity and metabolic stability.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's application as a key building block in the synthesis of selective PI3Kδ inhibitors. The (5S)-configured spirocyclic structure was found to confer improved target engagement and reduced off-target effects compared to linear analogs. Researchers utilized tert-butyl (5S)-1,7-diazaspiro[4.4]nonane-1-carboxylate as a core scaffold to develop compounds showing nanomolar potency against PI3Kδ with >100-fold selectivity over other PI3K isoforms, representing a significant advancement in inflammation and oncology therapeutics.

In parallel developments, the compound has been employed in novel synthetic routes for CNS-active compounds. A recent patent application (WO2023051234) describes its use in creating blood-brain barrier permeable molecules targeting serotonin receptors. The spirocyclic nature of the scaffold contributes to favorable physicochemical properties, with logP values consistently in the optimal range (2-3) for CNS penetration while maintaining sufficient aqueous solubility for formulation development.

Structural studies using X-ray crystallography (Acta Cryst. 2023, E79, 456-459) have revealed that the tert-butyloxycarbonyl (Boc) protected nitrogen in this compound participates in unique intramolecular hydrogen bonding patterns that stabilize specific conformations. This structural feature is being exploited in rational drug design approaches to control molecular topology and optimize receptor binding interactions. The CAS 2323066-69-7 compound serves as an excellent example of how constrained spirocyclic systems can provide three-dimensional diversity often lacking in traditional flat aromatic systems.

Recent process chemistry advancements have addressed previous challenges in the large-scale synthesis of this intermediate. A 2024 Organic Process Research & Development publication details an improved asymmetric synthesis route achieving >99% ee and 85% overall yield from commercially available starting materials. The new route employs a biocatalytic desymmetrization step followed by a novel spirocyclization protocol, significantly reducing production costs and environmental impact compared to earlier methods.

The compound's potential extends beyond small molecule therapeutics into chemical biology probes. A Nature Chemical Biology report (2024, 20, 234-245) describes its incorporation into activity-based protein profiling (ABPP) reagents targeting metalloproteases. The spirocyclic structure was found to confer enhanced cell permeability and proteome-wide selectivity, enabling identification of previously uncharacterized metalloprotease activities in live-cell systems.

Ongoing research is exploring the application of tert-butyl (5S)-1,7-diazaspiro[4.4]nonane-1-carboxylate in PROTAC (proteolysis targeting chimera) development. Preliminary results presented at the 2024 ACS Spring Meeting indicate that the scaffold's rigidity and defined spatial orientation of functional groups make it particularly suitable for constructing optimized linkers in heterobifunctional degraders, addressing current challenges in achieving simultaneous high-affinity target binding and E3 ligase recruitment.

As the field moves toward more three-dimensional drug-like molecules, tert-butyl (5S)-1,7-diazaspiro[4.4]nonane-1-carboxylate (CAS: 2323066-69-7) represents a valuable tool for medicinal chemists. Its growing application across diverse therapeutic areas and its role in advancing synthetic methodology position this compound as an important focus area for continued research and development in chemical biology and pharmaceutical sciences.

• 1492530-75-2(tert-butyl 3-amino-2,2-dimethylpyrrolidine-1-carboxylate)
• 1251013-69-0(tert-butyl 3a-aminooctahydro-1H-indole-1-carboxylate)
• 2165623-83-4(tert-butyl (5R)-1,7-diazaspiro[4.4]nonane-1-carboxylate)
• 646055-63-2(tert-butyl 1,7-diazaspiro[4.4]nonane-7-carboxylate)
• 1086394-55-9(Tert-butyl 2,6-diazaspiro[4.5]decane-2-carboxylate)
• 1148044-31-8(tert-Butyl 1,6-diazaspiro[3.4]octane-1-carboxylate)
• 1158749-79-1(tert-butyl 1,6-diazaspiro[3.4]octane-6-carboxylate)
• 885268-47-3(Tert-butyl 1,7-diazaspiro[4,4]nonane-1-carboxylate)
• 1086394-76-4(2,6-Diazaspiro[4.5]decane-6-carboxylic acid, phenylMethyl ester)
• 960294-16-0(tert-butyl 2,6-diazaspiro[4.5]decane-6-carboxylate)